Loading organizations...

NanoString Technologies is a technology company.
NanoString Technologies has raised $50.0M across 3 funding rounds.
NanoString Technologies has raised $50.0M in total across 3 funding rounds.
NanoString Technologies is focused on spatial biology, providing innovative solutions for single-cell research and molecular imaging.
NanoString Technologies has raised $50.0M in total across 3 funding rounds.
NanoString Technologies's investors include GE Ventures, Henri Termeer, AllianceBernstein, BioMed Ventures, Clarus Ventures, Draper Fisher Jurvetson, GE, Morgan Stanley, OVP Venture Partners, Oxford Finance, Silicon Valley Bank, Pascale Witz.
NanoString Technologies is a biotechnology company specializing in spatial biology tools for gene expression analysis, spatial transcriptomics, proteomics, and genomics.[1][2][3] It develops three core platforms—nCounter Analysis System, GeoMx Digital Spatial Profiler, and CosMx Spatial Molecular Imager—that enable researchers to profile tissues at bulk, regional, and single-cell/subcellular resolutions using FFPE or fresh frozen samples.[1][2][3][4][5][6] These products serve academic labs, pharmaceutical companies, and clinical researchers tackling complex diseases like oncology, neurodegeneration, and cardiovascular conditions by providing high-plex, direct digital detection without amplification biases.[3][4] NanoString addresses key challenges in biomarker discovery, cell atlasing, and cell-cell interactions, with strong growth evidenced by over 7,000 peer-reviewed publications and expanding applications in cell/gene therapy.[3][4][5]
NanoString Technologies was founded in 2003 in Seattle, Washington, by a team of scientists including Tom Geiss, who pioneered its core nCounter technology based on direct digital detection of nucleic acids using color-coded barcodes.[1] The idea emerged from frustrations with PCR amplification biases in gene expression profiling, leading to the nCounter system's launch around 2008 as a simpler alternative for 800-plex RNA/protein analysis.[2][4] Early traction came from oncology and immunology research, with pivotal expansions into spatial profiling via the 2018 acquisition of Astrolab (GeoMx DSP) and 2021 acquisition of Canopy Biosciences (CosMx SMI), integrating high-resolution imaging and multiomics.[3][5][6] These moves solidified its evolution from bulk expression tools to a comprehensive spatial biology leader.[1][3]
NanoString stands out in spatial biology through its integrated, amplification-free platforms that deliver high sensitivity and scalability:
NanoString rides the spatial biology boom, fueled by demand for understanding tissue microenvironments in immuno-oncology, neurodegeneration, and precision medicine amid advances in AI-driven data analysis.[3][5] Its timing aligns with the shift from bulk omics to spatial multiomics, where market forces like rising FFPE sample use in clinical trials and the need for subcellular insights favor non-destructive, high-plex tools over slower imaging alternatives.[2][6] By enabling cell atlasing and ligand-receptor mapping, NanoString influences drug discovery ecosystems, powering collaborations with pharma giants and accelerating therapies in cell/gene spaces.[4][5] It bridges histology and genomics, democratizing spatial data for broader research adoption.[3]
NanoString is poised to dominate spatial multiomics with CosMx expansions like the Whole Transcriptome Assay and AtoMx cloud platform, targeting deeper subcellular phenotyping and AI-integrated insights.[3][5] Trends in single-cell resolution, combo RNA/protein panels, and therapeutic biomarkers will propel growth, especially as spatial data volumes explode for machine learning models in oncology and neurobiology.[3][4] Its influence may evolve toward clinical diagnostics and automated workflows, solidifying its role as the go-to for translating spatial discoveries into actionable biology—echoing its origins in simplifying gene expression for real-world impact.[1][2]
NanoString Technologies has raised $50.0M across 3 funding rounds. Most recently, it raised $15.0M Series E in December 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2012 | $15.0M Series E | GE Ventures, Henri Termeer, AllianceBernstein, BioMed Ventures, Clarus Ventures, Draper Fisher Jurvetson, GE, Morgan Stanley, OVP Venture Partners | |
| Apr 6, 2012 | $15.0M Debt | Oxford Finance, Silicon Valley Bank | |
| Nov 7, 2011 | $20.0M Series D | Henri Termeer, BioMed Ventures, Clarus Ventures, Draper Fisher Jurvetson, Pascale Witz, OVP Venture Partners |